Prioritise research on vaccines for pregnant and breastfeeding women

Terra Manca; Françoise Baylis; Flor M. Munoz; Karina A. Top

doi:10.1016/S0140-6736(22)00379-8

Prioritise research on vaccines for pregnant and breastfeeding women

Terra Manca, Françoise Baylis, Flor M. Munoz, Karina A. Top

Résultat de recherche: Comment/debate › examen par les pairs

Langue d'origine	English
Pages (de-à)	890-893
Nombre de pages	4
Journal	The Lancet
Volume	399
Numéro de publication	10328
DOI	https://doi.org/10.1016/S0140-6736(22)00379-8
Statut de publication	Published - mars 5 2022
Publié à l'externe	Oui

Note bibliographique

Funding Information:
KAT has received grants from GlaxoSmithKline to her institution for work related to vaccines that could be given to pregnant women. FMM is a member of the Data and Safety Monitoring Boards for vaccines manufactured by Pfizer (respiratory syncytial virus [RSV]), Moderna (RSV, human metapneumovirus, parainfluenza, SARS-CoV-2, influenza), Virometix (RSV), and Meissa (RSV vaccines). FMM is an investigator in research supported by Pfizer (SARS-CoV-2 vaccines), Gilead (remdesivir), the US National Institutes of Health (safety of vaccines in pregnancy, Zika virus), and the US Centers for Disease Control and Prevention (respiratory virus epidemiology) for work directly or indirectly related to vaccines that could be given to pregnant women. TM has received funding from an IWK Health Centre postdoctoral fellowship grant and is funded by the Public Health Agency of Canada and Canadian Institutes of Health Research through a Canadian Immunization Research Network postdoctoral grant. FB declares no competing interests.

ASJC Scopus Subject Areas

General Medicine

PubMed: MeSH publication types

Journal Article

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Accès au document

10.1016/S0140-6736(22)00379-8

Autres fichiers et liens

Citer

@article{786d6bf55a9847b6ae8a1b1abc434e62,

title = "Prioritise research on vaccines for pregnant and breastfeeding women",

author = "Terra Manca and Fran{\c c}oise Baylis and Munoz, {Flor M.} and Top, {Karina A.}",

note = "Funding Information: KAT has received grants from GlaxoSmithKline to her institution for work related to vaccines that could be given to pregnant women. FMM is a member of the Data and Safety Monitoring Boards for vaccines manufactured by Pfizer (respiratory syncytial virus [RSV]), Moderna (RSV, human metapneumovirus, parainfluenza, SARS-CoV-2, influenza), Virometix (RSV), and Meissa (RSV vaccines). FMM is an investigator in research supported by Pfizer (SARS-CoV-2 vaccines), Gilead (remdesivir), the US National Institutes of Health (safety of vaccines in pregnancy, Zika virus), and the US Centers for Disease Control and Prevention (respiratory virus epidemiology) for work directly or indirectly related to vaccines that could be given to pregnant women. TM has received funding from an IWK Health Centre postdoctoral fellowship grant and is funded by the Public Health Agency of Canada and Canadian Institutes of Health Research through a Canadian Immunization Research Network postdoctoral grant. FB declares no competing interests.",

year = "2022",

month = mar,

day = "5",

doi = "10.1016/S0140-6736(22)00379-8",

language = "English",

volume = "399",

pages = "890--893",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10328",

}

TY - JOUR

T1 - Prioritise research on vaccines for pregnant and breastfeeding women

AU - Manca, Terra

AU - Baylis, Françoise

AU - Munoz, Flor M.

AU - Top, Karina A.

N1 - Funding Information: KAT has received grants from GlaxoSmithKline to her institution for work related to vaccines that could be given to pregnant women. FMM is a member of the Data and Safety Monitoring Boards for vaccines manufactured by Pfizer (respiratory syncytial virus [RSV]), Moderna (RSV, human metapneumovirus, parainfluenza, SARS-CoV-2, influenza), Virometix (RSV), and Meissa (RSV vaccines). FMM is an investigator in research supported by Pfizer (SARS-CoV-2 vaccines), Gilead (remdesivir), the US National Institutes of Health (safety of vaccines in pregnancy, Zika virus), and the US Centers for Disease Control and Prevention (respiratory virus epidemiology) for work directly or indirectly related to vaccines that could be given to pregnant women. TM has received funding from an IWK Health Centre postdoctoral fellowship grant and is funded by the Public Health Agency of Canada and Canadian Institutes of Health Research through a Canadian Immunization Research Network postdoctoral grant. FB declares no competing interests.

PY - 2022/3/5

Y1 - 2022/3/5

UR - http://www.scopus.com/inward/record.url?scp=85125524172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125524172&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(22)00379-8

DO - 10.1016/S0140-6736(22)00379-8

M3 - Comment/debate

C2 - 35248174

AN - SCOPUS:85125524172

SN - 0140-6736

VL - 399

SP - 890

EP - 893

JO - The Lancet

JF - The Lancet

IS - 10328

ER -